#China #Shanghai #Aphranel #MagiCCrystal #CaHA

Aphranel's Groundbreaking Presentation at SAAM 2025

Aphranel, a pioneering aesthetic brand based in China under SHANGHAI MOYANG BIOTECHNOLOGY, made its impressive debut at the 4th Scientific Congress of Aesthetic Medicine in Riyadh, Saudi Arabia (SAAM 2025). This prominent event drew over 2,500 participants from multiple countries, showcasing the latest innovations in aesthetic dermatology, laser therapies, and plastic surgery.

Unveiling MagiCCrystal CaHA

During the congress, Aphranel unveiled its Calcium Hydroxylapatite (CaHA) filler, branded as MagiCCrystal. The highlight of the presentation included collaborative demonstrations by esteemed Chinese physicians, Dr. Wang Wenting from Guangzhou Yestar and Dr. Chen Lorraine from Shanghai LELITE M. They illustrated advancements in regenerative materials and injection protocols, marking a significant step for the brand in international aesthetic practices.

Innovations in Technology

Aphranel's presentation focused on two key patented technologies:

• - ACD MT: This technology, characterized by its “raspberry-like” microparticle structure, enhances the filler’s performance.
• - PCD ETT: A physical gel reticulation technology that ensures a safe and predictable degradation profile is a hallmark of this innovation.

Both techniques aim to balance immediate modeling and long-term controlled collagen regeneration, making them suitable for modern aesthetic applications.

Leading Clinical Education

The event also featured live demonstrations where Dr. Wang showcased refined selection methods for injection layers and precise dose control. Meanwhile, Dr. Chen elaborated on a strategic framework emphasizing a “first deep, then superficial; first external, then internal” approach, which received substantial recognition from international peers and media.

This collaborative effort between Chinese experts at SAAM set a precedent in the global sharing of aesthetic techniques, allowing for learning and knowledge exchange.

Cultural Exchange and Technical Collaboration

Beyond the congress, the Aphranel team engaged with local aesthetic institutions to share technical expertise regarding regenerative materials and protocol design. This was not just a presentation but a genuine effort to foster professional dialogue between Chinese and Saudi counterparts, promoting a deeper understanding of innovations in the aesthetic field on both sides.

The Future of Aphranel

As the Chinese aesthetic industry matures, Aphranel is set to accelerate its international presence, leveraging its technological advantages and clinical validation. The company is keenly focused on enhancing collaborations and expanding market access to bring innovative regenerative technologies to a broader audience.

The pricing, availability, indications, and regulatory status of MagiCCrystal CaHA will vary by market, and clinical professionals are advised to consult local regulations and guidelines accordingly.

In conclusion, Aphranel’s presence at SAAM 2025 marks a crucial step in establishing its position in the global aesthetic market, showcasing its commitment to innovation and collaboration. As we move forward, the brand aims to play a vital role in shaping the future of regenerative aesthetics worldwide.